Cargando…

The clinicopathological significance and prognostic value of programmed death-ligand 1 in prostate cancer: a meta-analysis of 3133 patients

Background: Programmed death-ligand 1 (PD-L1) is considered an adverse factor predicting poor prognosis in various cancers, but the significance of PD-L1 expression for the prognosis of prostate cancer (PCa) is still unclear. We aimed to investigate the clinicopathological significance and prognosti...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shen, Haixiang, Liu, Jin, Sun, Guoliang, Yan, Libin, Li, Qinchen, Wang, Zhize, Xie, Liping
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals 2020
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7880326/ https://www.ncbi.nlm.nih.gov/pubmed/33318295 http://dx.doi.org/10.18632/aging.202248

Ejemplares similares

Clinicopathological characteristics of androgen receptor splicing variant 7 (AR-V7) expression in patients with castration resistant prostate cancer: A systematic review and meta‐analysis
por: Li, Qinchen, et al.
Publicado: (2021)

The Prognostic Value of Androgen Receptor Splice Variant 7 in Castration-Resistant Prostate Cancer Treated With Novel Hormonal Therapy or Chemotherapy: A Systematic Review and Meta-analysis
por: Wang, Zhize, et al.
Publicado: (2020)

Clinicopathological and prognostic significance of programmed death ligand 1 expression in Korean melanoma patients
por: Yun, Sumi, et al.
Publicado: (2019)

Prognostic and Clinicopathological Value of Programmed Death Ligand-1 in Breast Cancer: A Meta-Analysis
por: Guo, Yawen, et al.
Publicado: (2016)

Clinicopathological and prognostic significance of programmed death ligand-1 expression in breast cancer: a meta-analysis
por: Kim, Hye Min, et al.
Publicado: (2017)

Clinicopathologic Significance and Prognostic Value of Programmed Cell Death Ligand 1 (PD-L1) in Patients With Hepatocellular Carcinoma: A Meta-Analysis
por: Li, Jing-Hua, et al.
Publicado: (2018)

Clinicopathological and prognostic significance of programmed cell death ligand 1 expression in patients diagnosed with breast cancer: meta-analysis
por: Davey, M G, et al.
Publicado: (2021)

3133 Building Capacity for Community Engaged Research: Penn State University’s Faculty Fellowship Program
por: Wadsworth, Martha Ellen, et al.
Publicado: (2019)

The Clinicopathologic and Prognostic Significance of Programmed Cell Death Ligand 1 (PD-L1) Expression in Patients With Prostate Cancer: A Systematic Review and Meta-Analysis
por: Li, Yan, et al.
Publicado: (2019)

The clinicopathological significance and predictive value for immunotherapy of programmed death ligand-1 expression in Epstein-Barr virus-associated gastric cancer
por: Wei, Xiao-Li, et al.
Publicado: (2021)

The characteristics of androgen receptor splice variant 7 in the treatment of hormonal sensitive prostate cancer: a systematic review and meta-analysis
por: Wang, Zhize, et al.
Publicado: (2020)

Prognostic and Clinicopathological Value of Programmed Cell Death Ligand1 Expression in Patients With Small Cell Lung Cancer: A Meta-Analysis
por: Cai, Huarong, et al.
Publicado: (2020)

Clinicopathological analysis and prognostic significance of programmed cell death-ligand 1 protein and mRNA expression in non-small cell lung cancer
por: Kim, Hyojin, et al.
Publicado: (2018)

Hyperfijnstructuur van stabiel 25Mg en neutronrijke 31,33Mg kernen
por: Vervaeke, Barend
Publicado: (2012)

Prognostic significance of programmed death-1 and programmed death-ligand 1 expression in patients with esophageal squamous cell carcinoma
por: Chen, Kaiyan, et al.
Publicado: (2016)

Prognostic value of programmed death-ligand 1 in sarcoma: a meta-analysis
por: Zhu, Zhenhua, et al.
Publicado: (2017)

Clinicopathological Significances and Prognostic Value of PPFIA4 in Colorectal Cancer
por: Fu, Fangmei, et al.
Publicado: (2023)

Clinicopathologic Significance and Immunogenomic Analysis of Programmed Death-Ligand 1 (PD-L1) and Programmed Death 1 (PD-1) Expression in Thymic Epithelial Tumors
por: Song, Joon Seon, et al.
Publicado: (2019)

Expression of microRNA-3133 correlates with the prognosis in patients with clear cell renal cell carcinoma
por: Chen, Xiaoyan
Publicado: (2019)

Predictive Values of Programmed Cell Death-Ligand 1 Expression for Prognosis, Clinicopathological Factors, and Response to Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Inhibitors in Patients With Gynecological Cancers: A Meta-Analysis
por: Zhang, Chen, et al.
Publicado: (2021)

Correction: Li et al. Fringe Projection Profilometry Based on Saturated Fringe Restoration in High Dynamic Range Scenes. Sensors 2023, 23, 3133
por: Li, Hongru, et al.
Publicado: (2023)

Prognostic Significance of the Dynamic Change of Programmed Death-ligand 1 Expression in Patients with Multiple Myeloma
por: Guan, Jian, et al.
Publicado: (2019)

Correlation of PIK3CA mutation with programmed death ligand-1 (PD-L1) expression and their clinicopathological significance in colorectal cancer
por: Ahn, Ae Ri, et al.
Publicado: (2021)

Prognostic value of programmed death‐ligand 1 expression in patients with stage III colorectal cancer
por: Koganemaru, Shigehiro, et al.
Publicado: (2017)

The Prognostic Value of Circulating Soluble Programmed Death Ligand-1 in Cancers: A Meta-Analysis
por: Huang, Pei, et al.
Publicado: (2021)

Prognostic value of programmed death-ligand 1 status in Japanese patients with renal cell carcinoma
por: Uemura, Motohide, et al.
Publicado: (2021)

Prognostic Value of Galectin-9 Relates to Programmed Death-Ligand 1 in Patients With Multiple Myeloma
por: Lee, Byung-Hyun, et al.
Publicado: (2021)

Programmed death-ligand 1 expression and its correlation with clinicopathological parameters in gallbladder cancer
por: Kim, Ji Hye, et al.
Publicado: (2020)

Trends of Ulnar Collateral Ligament Reconstruction in the United States from 2003 to 2014: Analysis of 3,133 Patients
por: Idowu, Olumuyiwa A., et al.
Publicado: (2020)

Prognostic and clinicopathological roles of programmed death‐ligand 1 (PD‐L1) expression in thymic epithelial tumors: A meta‐analysis
por: Koh, Hyun Min, et al.
Publicado: (2020)

Distinct prognostic values of programmed death-ligand 1 and programmed cell death protein 1 in lung adenocarcinoma and squamous cell carcinoma patients
por: Wang, Shuo, et al.
Publicado: (2021)

Clinical significance of programmed death 1/programmed death ligand 1 pathway in gastric neuroendocrine carcinomas
por: Yang, Min-Wei, et al.
Publicado: (2019)

Prognostic and clinicopathological value of MUC1 expression in colorectal cancer: A meta-analysis
por: Li, Chao, et al.
Publicado: (2019)

Programmed Cell Death Ligand 1 in Breast Cancer: Technical Aspects, Prognostic Implications, and Predictive Value
por: Miglietta, Federica, et al.
Publicado: (2019)

Prognostic value of programmed cell death ligand-1 expression in ovarian cancer: an updated meta-analysis
por: Piao, Jinlan, et al.
Publicado: (2020)

Correction to: Prognostic value of programmed death-ligand 1 status in Japanese patients with renal cell carcinoma
por: Uemura, Motohide, et al.
Publicado: (2021)

Prognostic value of programmed cell death ligand-1 expression in breast cancer: A meta-analysis
por: Zhang, Yingzi, et al.
Publicado: (2020)

Prognostic significance of programmed death ligand-1 immunohistochemical expression in esophageal cancer: A meta-analysis of the literature
por: Yu, Weiwei, et al.
Publicado: (2018)

Prognostic significance of circulating soluble programmed death ligand-1 in patients with solid tumors: A meta-analysis
por: Wei, Wei, et al.
Publicado: (2018)

Programmed cell death‐ligand 1 expression in hepatocellular carcinoma and its correlation with clinicopathological characteristics
por: Mou, Haibo, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_korolsjcuv23hi40lt6utrqqdm